nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Diarrhoea—Chlorambucil—testicular cancer	0.00397	0.00397	CcSEcCtD
Roflumilast—Cardiac disorder—Etoposide—testicular cancer	0.00396	0.00396	CcSEcCtD
Roflumilast—Discomfort—Ifosfamide—testicular cancer	0.00396	0.00396	CcSEcCtD
Roflumilast—Hypersensitivity—Vinblastine—testicular cancer	0.00392	0.00392	CcSEcCtD
Roflumilast—Decreased appetite—Bleomycin—testicular cancer	0.0039	0.0039	CcSEcCtD
Roflumilast—Muscle spasms—Cisplatin—testicular cancer	0.0039	0.0039	CcSEcCtD
Roflumilast—Immune system disorder—Etoposide—testicular cancer	0.00385	0.00385	CcSEcCtD
Roflumilast—Mediastinal disorder—Etoposide—testicular cancer	0.00385	0.00385	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00382	0.00382	CcSEcCtD
Roflumilast—Asthenia—Vinblastine—testicular cancer	0.00382	0.00382	CcSEcCtD
Roflumilast—Infection—Ifosfamide—testicular cancer	0.00381	0.00381	CcSEcCtD
Roflumilast—Tremor—Cisplatin—testicular cancer	0.0038	0.0038	CcSEcCtD
Roflumilast—Nervous system disorder—Ifosfamide—testicular cancer	0.00376	0.00376	CcSEcCtD
Roflumilast—Ill-defined disorder—Cisplatin—testicular cancer	0.00376	0.00376	CcSEcCtD
Roflumilast—Renal failure acute—Epirubicin—testicular cancer	0.00374	0.00374	CcSEcCtD
Roflumilast—Skin disorder—Ifosfamide—testicular cancer	0.00373	0.00373	CcSEcCtD
Roflumilast—Feeling abnormal—Bleomycin—testicular cancer	0.0037	0.0037	CcSEcCtD
Roflumilast—Vomiting—Chlorambucil—testicular cancer	0.00369	0.00369	CcSEcCtD
Roflumilast—Malaise—Cisplatin—testicular cancer	0.00366	0.00366	CcSEcCtD
Roflumilast—Decreased appetite—Dactinomycin—testicular cancer	0.00364	0.00364	CcSEcCtD
Roflumilast—Diarrhoea—Vinblastine—testicular cancer	0.00364	0.00364	CcSEcCtD
Roflumilast—Dysgeusia—Etoposide—testicular cancer	0.00364	0.00364	CcSEcCtD
Roflumilast—Fatigue—Dactinomycin—testicular cancer	0.00361	0.00361	CcSEcCtD
Roflumilast—Back pain—Etoposide—testicular cancer	0.00359	0.00359	CcSEcCtD
Roflumilast—Muscle spasms—Etoposide—testicular cancer	0.00357	0.00357	CcSEcCtD
Roflumilast—Urticaria—Bleomycin—testicular cancer	0.00357	0.00357	CcSEcCtD
Roflumilast—Dizziness—Vinblastine—testicular cancer	0.00352	0.00352	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.0035	0.0035	CcSEcCtD
Roflumilast—Renal failure acute—Doxorubicin—testicular cancer	0.00347	0.00347	CcSEcCtD
Roflumilast—Myalgia—Cisplatin—testicular cancer	0.00345	0.00345	CcSEcCtD
Roflumilast—Feeling abnormal—Dactinomycin—testicular cancer	0.00345	0.00345	CcSEcCtD
Roflumilast—Nausea—Chlorambucil—testicular cancer	0.00345	0.00345	CcSEcCtD
Roflumilast—Ill-defined disorder—Etoposide—testicular cancer	0.00345	0.00345	CcSEcCtD
Roflumilast—Anxiety—Cisplatin—testicular cancer	0.00344	0.00344	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00343	0.00343	CcSEcCtD
Roflumilast—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00343	0.00343	CcSEcCtD
Roflumilast—Discomfort—Cisplatin—testicular cancer	0.00341	0.00341	CcSEcCtD
Roflumilast—Vomiting—Vinblastine—testicular cancer	0.00338	0.00338	CcSEcCtD
Roflumilast—Malaise—Etoposide—testicular cancer	0.00335	0.00335	CcSEcCtD
Roflumilast—Vertigo—Etoposide—testicular cancer	0.00334	0.00334	CcSEcCtD
Roflumilast—Decreased appetite—Ifosfamide—testicular cancer	0.00334	0.00334	CcSEcCtD
Roflumilast—Headache—Vinblastine—testicular cancer	0.00333	0.00333	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00331	0.00331	CcSEcCtD
Roflumilast—Abdominal pain—Dactinomycin—testicular cancer	0.00331	0.00331	CcSEcCtD
Roflumilast—Fatigue—Ifosfamide—testicular cancer	0.00331	0.00331	CcSEcCtD
Roflumilast—Hypersensitivity—Bleomycin—testicular cancer	0.00331	0.00331	CcSEcCtD
Roflumilast—Infection—Cisplatin—testicular cancer	0.00329	0.00329	CcSEcCtD
Roflumilast—Constipation—Ifosfamide—testicular cancer	0.00328	0.00328	CcSEcCtD
Roflumilast—Nervous system disorder—Cisplatin—testicular cancer	0.00325	0.00325	CcSEcCtD
Roflumilast—Asthenia—Bleomycin—testicular cancer	0.00322	0.00322	CcSEcCtD
Roflumilast—Skin disorder—Cisplatin—testicular cancer	0.00321	0.00321	CcSEcCtD
Roflumilast—Feeling abnormal—Ifosfamide—testicular cancer	0.00316	0.00316	CcSEcCtD
Roflumilast—Nausea—Vinblastine—testicular cancer	0.00316	0.00316	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00314	0.00314	CcSEcCtD
Roflumilast—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00314	0.00314	CcSEcCtD
Roflumilast—Discomfort—Etoposide—testicular cancer	0.00312	0.00312	CcSEcCtD
Roflumilast—Hypersensitivity—Dactinomycin—testicular cancer	0.00309	0.00309	CcSEcCtD
Roflumilast—Gastritis—Epirubicin—testicular cancer	0.00306	0.00306	CcSEcCtD
Roflumilast—Urticaria—Ifosfamide—testicular cancer	0.00305	0.00305	CcSEcCtD
Roflumilast—Abdominal pain—Ifosfamide—testicular cancer	0.00303	0.00303	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00301	0.00301	CcSEcCtD
Roflumilast—Infection—Etoposide—testicular cancer	0.00301	0.00301	CcSEcCtD
Roflumilast—Asthenia—Dactinomycin—testicular cancer	0.00301	0.00301	CcSEcCtD
Roflumilast—Influenza—Epirubicin—testicular cancer	0.00299	0.00299	CcSEcCtD
Roflumilast—Skin disorder—Etoposide—testicular cancer	0.00294	0.00294	CcSEcCtD
Roflumilast—Decreased appetite—Cisplatin—testicular cancer	0.00288	0.00288	CcSEcCtD
Roflumilast—Diarrhoea—Dactinomycin—testicular cancer	0.00287	0.00287	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—testicular cancer	0.00286	0.00286	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00286	0.00286	CcSEcCtD
Roflumilast—Vomiting—Bleomycin—testicular cancer	0.00286	0.00286	CcSEcCtD
Roflumilast—Infestation—Methotrexate—testicular cancer	0.00285	0.00285	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—testicular cancer	0.00285	0.00285	CcSEcCtD
Roflumilast—Depression—Methotrexate—testicular cancer	0.00284	0.00284	CcSEcCtD
Roflumilast—Rash—Bleomycin—testicular cancer	0.00283	0.00283	CcSEcCtD
Roflumilast—Gastritis—Doxorubicin—testicular cancer	0.00283	0.00283	CcSEcCtD
Roflumilast—Dermatitis—Bleomycin—testicular cancer	0.00283	0.00283	CcSEcCtD
Roflumilast—Hypersensitivity—Ifosfamide—testicular cancer	0.00283	0.00283	CcSEcCtD
Roflumilast—Influenza—Doxorubicin—testicular cancer	0.00276	0.00276	CcSEcCtD
Roflumilast—Asthenia—Ifosfamide—testicular cancer	0.00275	0.00275	CcSEcCtD
Roflumilast—Feeling abnormal—Cisplatin—testicular cancer	0.00273	0.00273	CcSEcCtD
Roflumilast—Weight decreased—Epirubicin—testicular cancer	0.0027	0.0027	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—testicular cancer	0.00269	0.00269	CcSEcCtD
Roflumilast—Pneumonia—Epirubicin—testicular cancer	0.00268	0.00268	CcSEcCtD
Roflumilast—Nausea—Bleomycin—testicular cancer	0.00267	0.00267	CcSEcCtD
Roflumilast—Infestation NOS—Epirubicin—testicular cancer	0.00266	0.00266	CcSEcCtD
Roflumilast—Infestation—Epirubicin—testicular cancer	0.00266	0.00266	CcSEcCtD
Roflumilast—Vomiting—Dactinomycin—testicular cancer	0.00266	0.00266	CcSEcCtD
Roflumilast—Rash—Dactinomycin—testicular cancer	0.00264	0.00264	CcSEcCtD
Roflumilast—Decreased appetite—Etoposide—testicular cancer	0.00264	0.00264	CcSEcCtD
Roflumilast—Diarrhoea—Ifosfamide—testicular cancer	0.00263	0.00263	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Etoposide—testicular cancer	0.00262	0.00262	CcSEcCtD
Roflumilast—Fatigue—Etoposide—testicular cancer	0.00261	0.00261	CcSEcCtD
Roflumilast—Constipation—Etoposide—testicular cancer	0.00259	0.00259	CcSEcCtD
Roflumilast—Urinary tract infection—Epirubicin—testicular cancer	0.00259	0.00259	CcSEcCtD
Roflumilast—Dizziness—Ifosfamide—testicular cancer	0.00254	0.00254	CcSEcCtD
Roflumilast—Hepatobiliary disease—Epirubicin—testicular cancer	0.00252	0.00252	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—testicular cancer	0.0025	0.0025	CcSEcCtD
Roflumilast—Sinusitis—Epirubicin—testicular cancer	0.0025	0.0025	CcSEcCtD
Roflumilast—Feeling abnormal—Etoposide—testicular cancer	0.0025	0.0025	CcSEcCtD
Roflumilast—Nausea—Dactinomycin—testicular cancer	0.00249	0.00249	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Roflumilast—Gastrointestinal pain—Etoposide—testicular cancer	0.00248	0.00248	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—testicular cancer	0.00247	0.00247	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—testicular cancer	0.00247	0.00247	CcSEcCtD
Roflumilast—Vomiting—Ifosfamide—testicular cancer	0.00244	0.00244	CcSEcCtD
Roflumilast—Hypersensitivity—Cisplatin—testicular cancer	0.00244	0.00244	CcSEcCtD
Roflumilast—Rash—Ifosfamide—testicular cancer	0.00242	0.00242	CcSEcCtD
Roflumilast—Dermatitis—Ifosfamide—testicular cancer	0.00242	0.00242	CcSEcCtD
Roflumilast—Urticaria—Etoposide—testicular cancer	0.00241	0.00241	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—testicular cancer	0.0024	0.0024	CcSEcCtD
Roflumilast—Abdominal pain—Etoposide—testicular cancer	0.0024	0.0024	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—testicular cancer	0.0024	0.0024	CcSEcCtD
Roflumilast—Asthenia—Cisplatin—testicular cancer	0.00237	0.00237	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—testicular cancer	0.00237	0.00237	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—testicular cancer	0.00235	0.00235	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00233	0.00233	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—testicular cancer	0.00231	0.00231	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—testicular cancer	0.00231	0.00231	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—testicular cancer	0.0023	0.0023	CcSEcCtD
Roflumilast—Nausea—Ifosfamide—testicular cancer	0.00228	0.00228	CcSEcCtD
Roflumilast—Diarrhoea—Cisplatin—testicular cancer	0.00226	0.00226	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—testicular cancer	0.00224	0.00224	CcSEcCtD
Roflumilast—Hypersensitivity—Etoposide—testicular cancer	0.00223	0.00223	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—testicular cancer	0.00222	0.00222	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—testicular cancer	0.00222	0.00222	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—testicular cancer	0.00222	0.00222	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—testicular cancer	0.00218	0.00218	CcSEcCtD
Roflumilast—Asthenia—Etoposide—testicular cancer	0.00218	0.00218	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—testicular cancer	0.00217	0.00217	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Roflumilast—Back pain—Methotrexate—testicular cancer	0.00215	0.00215	CcSEcCtD
Roflumilast—Vomiting—Cisplatin—testicular cancer	0.0021	0.0021	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—testicular cancer	0.0021	0.0021	CcSEcCtD
Roflumilast—Rash—Cisplatin—testicular cancer	0.00209	0.00209	CcSEcCtD
Roflumilast—Dermatitis—Cisplatin—testicular cancer	0.00208	0.00208	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—testicular cancer	0.00208	0.00208	CcSEcCtD
Roflumilast—Diarrhoea—Etoposide—testicular cancer	0.00207	0.00207	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—testicular cancer	0.00206	0.00206	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Roflumilast—Tension—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—testicular cancer	0.00202	0.00202	CcSEcCtD
Roflumilast—Back pain—Epirubicin—testicular cancer	0.00201	0.00201	CcSEcCtD
Roflumilast—Malaise—Methotrexate—testicular cancer	0.00201	0.00201	CcSEcCtD
Roflumilast—Dizziness—Etoposide—testicular cancer	0.002	0.002	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—testicular cancer	0.002	0.002	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—testicular cancer	0.002	0.002	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—testicular cancer	0.002	0.002	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Roflumilast—Nausea—Cisplatin—testicular cancer	0.00197	0.00197	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—testicular cancer	0.00194	0.00194	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—testicular cancer	0.00193	0.00193	CcSEcCtD
Roflumilast—Vomiting—Etoposide—testicular cancer	0.00193	0.00193	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—testicular cancer	0.00193	0.00193	CcSEcCtD
Roflumilast—Rash—Etoposide—testicular cancer	0.00191	0.00191	CcSEcCtD
Roflumilast—Dermatitis—Etoposide—testicular cancer	0.00191	0.00191	CcSEcCtD
Roflumilast—Headache—Etoposide—testicular cancer	0.0019	0.0019	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—testicular cancer	0.00189	0.00189	CcSEcCtD
Roflumilast—Tension—Doxorubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00188	0.00188	CcSEcCtD
Roflumilast—Malaise—Epirubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—testicular cancer	0.00187	0.00187	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—testicular cancer	0.00186	0.00186	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Roflumilast—Infection—Methotrexate—testicular cancer	0.0018	0.0018	CcSEcCtD
Roflumilast—Nausea—Etoposide—testicular cancer	0.0018	0.0018	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—testicular cancer	0.00179	0.00179	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—testicular cancer	0.00178	0.00178	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—testicular cancer	0.00176	0.00176	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00176	0.00176	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—testicular cancer	0.00175	0.00175	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Roflumilast—Infection—Epirubicin—testicular cancer	0.00169	0.00169	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00165	0.00165	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—testicular cancer	0.00164	0.00164	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—testicular cancer	0.00163	0.00163	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00163	0.00163	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—testicular cancer	0.0016	0.0016	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Roflumilast—Infection—Doxorubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—testicular cancer	0.0015	0.0015	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—testicular cancer	0.00148	0.00148	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Roflumilast—Constipation—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—testicular cancer	0.00144	0.00144	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—testicular cancer	0.00144	0.00144	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Roflumilast—Hypersensitivity—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Roflumilast—Rash—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Roflumilast—Headache—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Roflumilast—Asthenia—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Roflumilast—Nausea—Methotrexate—testicular cancer	0.00108	0.00108	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Roflumilast—Rash—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Roflumilast—Headache—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Roflumilast—Nausea—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Roflumilast—Vomiting—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Roflumilast—Rash—Doxorubicin—testicular cancer	0.000991	0.000991	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—testicular cancer	0.00099	0.00099	CcSEcCtD
Roflumilast—Headache—Doxorubicin—testicular cancer	0.000985	0.000985	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—testicular cancer	0.000934	0.000934	CcSEcCtD
